PT Kimia Farma (Persero) Tbk - SMA, D3, S1 Fresh Graduate Job Fair Program Kimia Farma December 2018

PT Kimia Farma (Persero) Tbk / kimiafarma.co.id

PT Kimia Farma (Persero) Tbk - Kimia Farma is a foremost state-owned pharmaceutical company in Indonesia, headquartered in Jakarta. Kimia Farma has its business activities focused in pharmaceutical manufacturing, pharmaceutical trade and distribution, retail pharmacy, health clinic, laboratories and optical clinics. Kimia Farma is a public-listed company and is listed on the Indonesia Stock Exchange (IDX) under reference code KAEF. As today, the Government of Indonesia holds 90.025% shares in Kimia Farma. Other remaining shares in Kimia Farma was owned by management/employee (0.127%) and public (9.848%).

Kimia Farma now has 7 production plant; Plant Jakarta, Plant Bandung, Plant Semarang, Plant Watudakon, Plant Garam Farmasi, Plant Medan, and lant Rapid Test. Kimia Farma also supported by 1 research and development office at Bandung and 1 central logistic unit Jakarta. Kimia Farma also supported 6 directly-owned subsidiaries and affiliated companies, namely PT Kimia Farma Trading & Distribution, PT Kimia Farma Apotek, PT Sinkona Indonesia Lestari, PT Kimia Farma Diagnostik, PT Kimia Farma Sungwun Pharmacopia and PT Asuransi InHealth Indonesia. As of the end of September 2018, Kimia Farma has 1,135 pharmacies, 530 health clinics, 55 clinical laboratories, and 10 optics throughout Indonesia.

In term of financial performance, Kimia Farma is running well in the third quarter of 2018 (3Q18, ended in 30 September 2018). According to information found in PT Kimia Farma (Persero) Tbk 2018 Third Quarter Report as quoted by JobsCDC.com, Kimia Farma reported total net revenue of Rp5.31 trillion (unaudited) as at the end of September 2018. This number is up 23.37% year-on-year (YOY) as compared with Rp4.30 trillion (unaudited) in the same period previous year. Kimia Farma booked total profit of Rp483.29 billion in the third quarter of 2018 or 45.31% growth as compared with Rp332.60 billion in the third quarter of 2017.

To support the business expansion and its organic growth, PT Kimia Farma (Persero) Tbk invites qualified candidates to fulfill the position as follows

Pharmacist
Education major : Pharmacy

Pharmacist for DAWAA (Saudi Arabia)
Education major : Pharmacy, S2 Pharmacy (only for Male)

Secretary of the Board of Directors
Education major : D3 Secretary, D3 Niaga Administration, D3 English, D3 Business Administration.

Engineering & Production
Education major : D3/S1 Civil Engineering, D3 Electromedics, D3 Electrical Engineering.

Frontliner
Education major : D3/S1 any major (only for Female).

Information Technology
Education major : D3/S1 Information System, D3/S1 Information Management.

Sales & Marketing
Education major : D3/S1 any major, priority experienced in the field of health laboratories.

Marcks' Venus Aesthetic Clinic
Education major : Pharmacy, Senior High School (Therapist).

Property
Education major : S1 Civil Engineering, S1 Architect. Priority experienced in the field.

Business Development
Education major : S1 Architect, S1 Civil Engineering.

General Requirements

• D3 in any related major (maximum age of 26 years old).
• S1 in any related major (maximum age of 27 years old).
• Have experience in the same field is an advantage.
• Minimum GPA of 3.00 (scale 4.00).
• Minimum Accreditation B for PTN (all major).
• Minimum Accreditation A for PTS (all major).
• Fresh graduate are welcome to apply.
• Energetic, hard worker, high integrity and well groomed.
• Single/not married.

For further information, please refer official source from PT Kimia Farma (Persero) Tbk on following link below. If you match the profile and are interested in this exiting career opportunity, please apply in confidence by filling online application form at https://bit.ly/jobfairkaef (Your application will go directly to Kimia Farma). Closing date 31 December 2018. Application will be treated strictly confidential and only short-listed candidates will receive responses. (JobsCDC.com / Source)